Navigation Links
Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
Date:1/12/2009

SHELTON, Conn., Jan. 12 /PRNewswire/ -- Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist, CR845. The Phase II multi-center, double-blind, placebo-controlled trial will be conducted in the United States and will evaluate the analgesic efficacy and safety of intravenous CR845 during the post-operative period in women following laparoscopic-assisted hysterectomy. The trial is expected to enroll 120 patients, who will be randomly selected for treatment with one of two doses of CR845 or placebo. Results from the study are expected in the second half of 2009.

The Company also expects to initiate a Phase I study of an oral formulation of CR845 later in 2009.

About CR845

A previous Phase Ia single-center clinical trial of intravenous CR845 evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of the compound in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 54 healthy male and female volunteers. CR845 was shown to be safe at all doses investigated, with no reports of serious side effects or adverse central nervous system activity. Linear, dose-proportional increases in systemic exposure to CR845 were observed. Low doses of CR845 stimulated physiological biomarkers of peripheral kappa opioid receptor activity, and also produced plasma levels of drug associated with analgesic efficacy in multiple preclinical studies.

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibited analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral administration. Oral bioavailability was confirmed in multiple species. In con
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
9. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
10. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
11. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... ,, RALEIGH,N.C.,Nov.24/PRNewswire/--Pharmac...ningsolutionsforthepharmaceuticalandbiotechindustr...pitalMarketplace .Thenew HospitalMarketplace e-cou...sExcellence(TM) series,acomprehensiveseriesofe-cou...edmanagedmarketsknowledgeforcommercialprofessional...
(Date:11/24/2009)... ,, WASHINGTON,Nov.24/PRNewswire-USNewswire/...ompaniesaretesting97medicinesandvaccinestotreatorp...reportreleasedtodaybythePharmaceuticalResearchandM...anniversaryof"WorldAIDSDay"-aglobalawarenesscampai...ealthonProgrammesforAIDSPrevention. ,, "Wearegr...
(Date:11/24/2009)... ,, BEIJING,Nov.24/PRNewswire-Asia-FirstCall...S)("Lotus"orthe"Company")agrowingdeveloperand,prod...fpharmaceutical,productsinthePeople,sRepublicChina...memberoftheBeijingpharmaceuticaldelegation. ,...alConventionCenter,Chengdu ,, TheBeijingdeleg...
Breaking Medicine Technology:Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 1BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 3BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 4BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 5Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 1Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies 14167 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 1Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 3Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 4Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 5Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 7Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 8
...un 28, 2007 - Cytogen,Corporation (NASDAQ: CYTO) r...n study evaluating QUADRAMET(R) (samarium Sm-153,l...b (Velcade(R),Millennium Pharmaceuticals, Inc.) i...om 33 patients were presented today in a,poster ti...ium,(Sam) in Multiple Myeloma," by James Berenson,...
...ed with VELCADE, lenalidomide,and dexamethasone , ...llennium,Pharmaceuticals, Inc. (Nasdaq: MLNM) toda...r clinical trials of VELCADE based,therapies that ...ission / complete response(1) (CR) rates in newly ...ta were presented at the,prestigious 11th Internat...
Other Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
(Date:11/24/2009)...SHINGTON,Nov.24/PRNewswire/--TheUnionLaborLifeInsu...hasalignedwithVSP(®),()thenation,slargestvisi...oninsuranceproductstounions,uniontrustfunds,unione...ccesspointsofferingservicesincludingcomprehensivee...nderstandhowimportantqualityeyecareis,"statedBruce...
(Date:11/24/2009)...s that quitting improves heart prospects, but canc...althDay News) -- A new study offers yet more proof...m heart disease and cancer. , Researchers follo...mokers, formers smokers and nonsmokers for three y...times more likely to die of cancer, 2.26 times mor...
(Date:11/24/2009)...x as an example, study finds no added use but high... News) -- Direct-to-consumer drug ads may contribu...udy that examined sales of the widely used antipla... of data from 1999 to 2005 for 27 state Medicaid p...for clopidogrel did not increase people,s use of t...
(Date:11/24/2009)...WYORK,Nov.24/PRNewswire/--TheGuardianLifeInsurance...feinsurersandaleadingproviderofemployeebenefitsfor...mpanywillcontinuetofollowitscurrentinsurancecovera...esareconsistentwiththeAmericanCancerSocietyandAmer...graphyscreenings. ,, Recently,TheU.S.Preventive...
(Date:11/24/2009)...lease is available in French and Spanish . ,...e found a suicide gene, called ,gene E, which lea...t, lung and colon cancer, and prevents their growt... to fight cancer can reduce the potent drugs that ...ive treatment for cancer. , This research was co...
Breaking Medicine News(10 mins):Health News:Union Labor Life & VSP Vision Care Align to Offer Vision Insurance Products 2Health News:Smokers Double Their Risk for Heart Disease 2Health News:Advertising to Consumers May Raise Drug Prices 2Health News:Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage 2
...shington Joins Nationwide Campaign to Close the Ga...-Income Women and Women of Color, SEATTLE, Nov. 8...cancer incidence in the United States. Tonight, th...t for,screening programs for low-income women and ...
...rmatologists Can Help Manage the Effects of Stress... Nails, NEW YORK, Nov. 8 Pending job cuts at...orce. An unexpected surgery. What do,they all have...atologic problems, such as acne, brittle nails or ...
...MBURG, Germany and OXFORD, England, November 8 /PR...Exchange: EVT) will report its financial,results f...er 2007. The Company is going to hold a conferenc.... US time (East Coast), Conference call numbers: ...
.... Auayporn Nademanee of City of Hope leads study s...el therapy, ARCADIA, Calif. and DUARTE, Calif., N...s selected an abstract written by Dr.,Auayporn Nad...obal Medical Director for StemCyte, as one of four...
...THESDA, Md., Nov. 8 World Diabetes Day, November ... in more than 160 countries,and by others with an ...on,of diabetes in children and adolescents," provi... National Institutes of Health (NIH), researchers ...
...inful Eye Condition Can Occur in Up to 40 Percent ...s (Spinal Arthritis), ABBOTT PARK, Ill., Nov. 8 ...eated with Abbott,s HUMIRA(R) showed,a decrease in...spine, and may also be associated with other infla...
Other Medicine News:Health News:Puget Sound Komen for the Cure, Former First Lady Mona Locke, Washington Health Leaders and Breast Cancer Survivors Call for Action to Reduce State's High Breast Cancer Incidence 2Health News:Feeling Stressed? 2Health News:Feeling Stressed? 3Health News:Feeling Stressed? 4Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 2Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 3Health News:Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program 4Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 2Health News:World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response 3Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 2Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 3Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 4Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 5Health News:Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab) 6
The Link Ribbed Hip Stem
The SG stem
The KR stem
The MY stem
Medicine Products: